Table 1.
Baseline characteristics of individuals.
| Characteristic | Diagnosis data set (cross-sectional) (n = 493 individuals) |
Biomarker data set individuals (n = 494 individuals) |
Biomarker data set visits (longitudinal) (n = 726 visits) |
Overlap (n = 485 individuals) |
|---|---|---|---|---|
| Diagnosis, n (%) | ||||
| Dementia-AD | 44 (8.9%) | 43 (8.7%) | 44 (6.1%) | 43 (8.9%) |
| MCI | 40 (8.1%) | 42 (8.5%) | 45 (6.2%) | 40 (8.2%) |
| CU | 409 (82.9%) | 409 (82.8%) | 637 (87.7%) | 402 (82.9%) |
| Primary Race, n (%) | ||||
| White | 472 (95.7%) | 473 (95.7%) | 693 (95.5%) | 464 (95.7%) |
| Black or African American | 16 (3.3%) | 16 (3.2%) | 22 (3.03%) | 16 (3.3%) |
| American Indian or Alaska Native | 3 (0.6%) | 3 (0.6%) | 4 (0.6%) | 3 (0.6%) |
| Asian | 1 (0.2%) | 1 (0.2%) | 3 (0.4%) | 1 (0.2%) |
| Other | 1 (0.2%) | 1 (0.2%) | 4 (0.6%) | 1 (0.2%) |
| Sex, n (%) | ||||
| Male | 191 (38.7%) | 191 (38.7%) | 273 (39.4%) | 189 (39.0%) |
| Female | 302 (61.3%) | 303 (61.3%) | 453 (65.4%) | 296 (61.0%) |
| CSF amyloid and tau status, n (%) | ||||
| A−T− | 319 (64.7%) | 324 (65.6%) | 500 (68.9%) | 317 (65.4%) |
| A+T− | 61 (12.4%) | 59 (11.9%) | 85 (11.7%) | 59 (12.2%) |
| A−T+ | 20 (4.1%) | 20 (4.0%) | 28 (3.8%) | 19 (3.9%) |
| A+T+ | 85 (17.2%) | 84 (17.0%) | 102 (14.0%) | 83 (17.1%) |
| Not measured | 8 (1.6%) | 7 (1.4%) | 11 (1.5%) | 7 (1.4%) |
| Age in years mean, (SD) | 64.1 (8.9) | 63.1 (8.9) | 63.4 (8.3) | 64.0 (9.0) |
| PiB Global DVR, n, (SD) | 179 (9.4) | N/A | N/A | 179 (9.4) |
| PiB Positive, n, (%) | 50 (27.9%) | N/A | N/A | 50 (27.9%) |
| Number of visits | ||||
| 1 | 493 | 357 | N/A | N/A |
| 2 | 0 | 65 | N/A | N/A |
| 3 | 0 | 49 | N/A | N/A |
| 4 | 0 | 23 | N/A | N/A |
For demographics information in the sex- and amyloid-stratified groups, see Supplemental Tables 1 and 2. For data on missingness by biomarker and metabolite, see Supplemental Table 4. All individuals with PiB Global DVR measurements were present in the Diagnosis data set. For additional information on participant cardiovascular factors, see Supplemental Table 3
Abbreviations: AD, Alzheimer’s disease; MCI, mild cognitive impairment; CU, cognitively unimpaired; CSF, cerebrospinal fluid; PiB, Pittsburgh Compound B; DVR, distribution volume ratio; SD, standard deviation.